Skin & Subcutaneous Tissue

Bullous pemphigoid: diagnosis and management

Clinical Overview and When to Suspect Bullous Pemphigoid

— Peak incidence age 70–80 years; rare under 60.

— Incidence rising, partly due to drug-associated cases and aging population.

— No strong sex predilection; slight male predominance in some series.

— Elderly patient with tense, fluid-filled bullae on erythematous or urticarial base, favoring flexures, axillae, groin, medial thighs, lower abdomen.

— Intense pruritus that may precede blisters by weeks to months (the "pre-bullous" or "non-bullous" phase) — often misdiagnosed as eczema, urticaria, or scabies.

— Mucosal involvement is uncommon (~10–30%, usually mild oral), distinguishing it from pemphigus vulgaris and mucous membrane pemphigoid.

— Drugs: gliptins (DPP-4 inhibitors — sitagliptin, vildagliptin), PD-1/PD-L1 immune checkpoint inhibitors, loop diuretics (furosemide), penicillamine, sulfasalazine.

— Neurologic disease: Parkinson disease, dementia, stroke, multiple sclerosis — strong epidemiologic link; consider BP in bedbound elderly with new pruritic eruption.

— Psoriasis treated with phototherapy; rare paraneoplastic associations (weaker than for pemphigus).

Definition: Bullous pemphigoid (BP) is the most common autoimmune subepidermal blistering disease in adults, caused by IgG autoantibodies against hemidesmosomal antigens BP180 (BPAG2, collagen XVII) and BP230 (BPAG1) at the dermal–epidermal junction.

Epidemiology:

When to suspect (high-yield triggers):

Common precipitants/associations:

Step 3 management: In an elderly patient on a DPP-4 inhibitor who presents with tense bullae or unexplained chronic pruritus, stop the gliptin and refer for biopsy with direct immunofluorescence — drug-induced BP often improves with withdrawal alone.

Prognosis: Chronic relapsing course over 1–5 years; 1-year mortality 10–40% in elderly, driven more by comorbidities, infection, and immunosuppression complications than skin disease itself.

Presentation Patterns and Key History

— Prodromal/non-bullous phase (weeks to months): intractable pruritus, eczematous or urticarial plaques, excoriations; often treated unsuccessfully as "senile pruritus," contact dermatitis, or drug rash.

— Bullous phase: sudden appearance of tense, dome-shaped bullae 1–4 cm, clear or hemorrhagic fluid, on erythematous, urticarial, or normal-appearing skin; bullae do not rupture easily because the split is subepidermal.

— Medication review with explicit attention to: gliptins, checkpoint inhibitors (nivolumab, pembrolizumab), furosemide, spironolactone, ACE inhibitors, NSAIDs, antibiotics (amoxicillin, ciprofloxacin), neuroleptics. Document start dates relative to rash onset (typically weeks to months).

— Neurologic history: dementia, Parkinson, prior stroke — supports diagnosis and influences treatment tolerance.

— Functional status, caregiver support, fall risk, swallowing — all affect therapy choice.

— Vaccination history (occasional post-vaccine BP reports) and recent infections.

— Localized BP: isolated to pretibial area or a single body region — milder course.

— Vesicular BP: small grouped vesicles resembling dermatitis herpetiformis.

— Erythrodermic, nodular (pemphigoid nodularis), or dyshidrosiform variants.

Two-phase clinical course:

Distribution: flexor forearms, axillae, inner thighs, groin, lower abdomen, and lower legs; often symmetric. Scalp and face usually spared (vs. pemphigus foliaceus).

Symptoms: severe pruritus is the dominant complaint; burning or pain over bullae; mucosal lesions when present are usually transient oral erosions without scarring.

Critical history to obtain:

Variant presentations:

Board pearl: A nursing-home patient with months of unexplained itching, eczematous patches, and normal scabies prep who then develops tense blisters — think BP and biopsy. The non-bullous prodrome is the most commonly missed early presentation on exams.

Physical Exam Findings

— Tense bullae 1–4 cm with clear or serosanguineous fluid on erythematous, urticarial, or normal skin.

— Nikolsky sign negative (lateral pressure does not extend the blister) — contrasts with pemphigus vulgaris where Nikolsky is positive.

— Asboe-Hansen sign (gentle pressure on intact bulla does not extend it laterally) — also negative in BP.

— Bullae heal without scarring and typically without milia (mild post-inflammatory hyperpigmentation common).

— Flexural predominance: axillae, antecubital/popliteal fossae, groin, inner thighs, lower abdomen, lower legs.

— Spares mucous membranes in most cases; oral erosions if present are small and few.

— Palms/soles, scalp, face usually spared.

— BP: tense bullae, Nikolsky negative, subepidermal split, elderly, minimal mucosal disease.

— Pemphigus vulgaris: flaccid bullae, Nikolsky positive, intraepidermal split, middle-aged, prominent painful oral erosions.

— Dermatitis herpetiformis: grouped vesicles on extensor surfaces (elbows, knees, buttocks), intensely pruritic, associated with celiac.

— Estimate body surface area involved — guides severity (mild <10%, moderate 10–30%, severe >30% or >10 new blisters/day).

— Look for secondary infection: honey-colored crust, purulence, surrounding cellulitis, fever — common in extensive disease and a leading cause of mortality.

— Assess hydration, nutritional status, pressure-injury risk, and functional decline — extensive denuded skin causes fluid/protein loss similar to a partial-thickness burn.

Primary lesions:

Secondary lesions: excoriations, eczematous plaques, urticarial wheals (especially in non-bullous phase), erosions with peripheral collarettes of epidermis after rupture, crusts.

Distribution map to note on exam:

Key distinction:

General assessment for Step 3:

Board pearl: "Tense bullae on an erythematous, urticarial base in an 80-year-old, Nikolsky negative" is the single most testable physical exam picture for BP.

Diagnostic Workup — Initial Labs and Bedside Studies

— Lesional biopsy (4 mm punch) from edge of fresh bulla → routine H&E in formalin. Histology shows subepidermal blister with eosinophil-rich infiltrate; eosinophilic spongiosis may be the only finding in the non-bullous phase.

— Perilesional biopsy (within 1 cm of an active lesion, on normal-appearing skin) → placed in Michel's or Zeus transport medium (not formalin) for direct immunofluorescence (DIF).

— Shows linear deposition of IgG and/or C3 along the basement membrane zone (BMZ).

— C3 is positive in >90%; IgG in ~70–90%. Linear C3 at the DEJ is the most sensitive single DIF finding.

— CBC with differential (peripheral eosinophilia in ~50%), BMP, LFTs, glucose/HbA1c (steroid planning), albumin, lipid panel.

— Hepatitis B and C serologies, HIV, QuantiFERON or PPD (before systemic immunosuppression).

— Vitamin D, bone density planning if prolonged steroids anticipated.

— TPMT and/or NUDT15 activity if azathioprine is being considered.

— Pregnancy test in any reproductive-age patient (rare in BP but mandatory before immunosuppressants/methotrexate).

— Bacterial swab and culture of any crusted/eroded lesions if infection suspected.

— Photograph lesions for longitudinal monitoring.

Diagnosis requires biopsy + immunofluorescence; clinical features alone are insufficient because steroid therapy carries real risk in the elderly.

Skin biopsy — two specimens, two sites:

Direct immunofluorescence (gold standard for diagnosis):

Initial bloodwork — baseline before therapy:

Bedside adjuncts:

CCS pearl: On a CCS case, the correct opening sequence is: history → focused skin exam → punch biopsy of lesional skin (H&E) and perilesional skin (DIF in Michel's medium) → CBC, CMP, glucose, HBV/HCV, HIV, TB screen — before ordering systemic steroids. Ordering prednisone before biopsy is a classic trap because it can blunt DIF findings within days.

Diagnostic Workup — Advanced and Confirmatory Studies

— Patient serum tested on monkey esophagus or salt-split human skin substrate.

— On salt-split skin, BP antibodies bind the epidermal (roof) side of the split — distinguishes BP from epidermolysis bullosa acquisita (EBA) and bullous SLE, which bind the dermal (floor) side.

— Titers correlate loosely with disease activity.

— Anti-BP180 NC16A — sensitivity ~85%, correlates with disease activity and is the preferred marker for monitoring response and predicting relapse.

— Anti-BP230 — less sensitive (~60–70%), does not correlate as well with activity, but increases overall diagnostic yield when added.

— Rising anti-BP180 titer on a tapering steroid often heralds relapse before clinical signs.

— Repeat biopsy from a fresh perilesional site.

— Send serum for BIOCHIP multiplex assay or salt-split IIF.

— Consider immunoblot/immunoprecipitation at a reference lab to identify BP180/BP230 or rule out EBA (type VII collagen), p200 pemphigoid, anti-laminin-332 mucous membrane pemphigoid (the last carries a paraneoplastic association).

— Routine cancer screening age-appropriate only — BP is not strongly paraneoplastic (unlike paraneoplastic pemphigus or anti-laminin-332 MMP). Do not order whole-body CT reflexively.

— Screen for occult malignancy only if atypical features, refractory disease, or anti-laminin-332 antibodies present.

— DEXA scan if anticipated steroid course >3 months at ≥7.5 mg/day prednisone equivalent.

— Eye exam baseline (cataracts, glaucoma risk on chronic steroids).

Indirect immunofluorescence (IIF):

ELISA for circulating autoantibodies:

When DIF is negative but suspicion remains:

Imaging/malignancy workup:

Pre-treatment evaluation:

Board pearl: Salt-split skin IIF showing epidermal (roof) binding = BP; dermal (floor) binding = EBA or bullous SLE. This single test is the highest-yield way to separate clinically similar subepidermal bullous diseases on the boards.

Severity Stratification and Management Logic

— Mild/limited: <10% BSA, <10 new blisters/day, localized.

— Moderate–severe: ≥10% BSA, ≥10 new blisters/day, rapid progression, or mucosal involvement.

— Validated tool: BPDAI (Bullous Pemphigoid Disease Area Index) — used in research and increasingly in clinic.

— Step 1 — Identify and remove triggers: discontinue suspected drugs (especially DPP-4 inhibitors); replace with alternative diabetes agent (SGLT2 inhibitor or insulin). Document in problem list as adverse drug reaction.

— Step 2 — Topical therapy first for mild/moderate disease.

— Step 3 — Systemic therapy for moderate-severe or topical failure.

— Step 4 — Steroid-sparing agent early to limit cumulative steroid exposure in elderly.

— High-potency topical clobetasol 0.05% ointment to active lesions BID; emerging evidence and European guidelines support whole-body clobetasol (10–40 g/day) even in moderate disease — equally effective as oral prednisone with fewer systemic side effects in the elderly.

— Adjunct: doxycycline 100 mg BID ± nicotinamide 500 mg TID for anti-inflammatory effect (steroid-sparing, well tolerated).

— Oral prednisone 0.5 mg/kg/day (typically 0.5–0.75 mg/kg) until disease control (no new blisters × 2 weeks), then taper over 6–9 months.

— Add steroid-sparing agent early: azathioprine, mycophenolate mofetil, or methotrexate.

— Rituximab or omalizumab/dupilumab for refractory disease (emerging data; dupilumab increasingly used given Th2/eosinophil-driven pathogenesis).

Severity assessment (drives therapy):

Management framework:

Mild/localized BP:

Moderate–severe BP:

Step 3 management: In a frail 82-year-old with moderate BP and uncontrolled diabetes, whole-body topical clobetasol + doxycycline/nicotinamide is often preferred over high-dose oral prednisone — equal efficacy, lower mortality in trials (Joly et al.). Choose systemic only if topical impractical due to extent or caregiver limitations.

Pharmacotherapy — First-Line Drug Regimens

— Clobetasol propionate 0.05% cream/ointment, applied to entire body (sparing face) BID, 10–40 g/day until control, then taper frequency over 4 months.

— Adverse effects: skin atrophy, striae, HPA suppression with high-volume use; monitor glucose and BP.

— Prednisone 0.5 mg/kg/day PO (max ~60–80 mg) for moderate-severe disease; control usually within 1–4 weeks.

— Taper: reduce by ~25% every 2–4 weeks once no new blisters × 2 weeks; aim for ≤10 mg/day by 4–6 months, off by 9–12 months.

— Avoid doses >0.75 mg/kg/day — increased mortality in elderly without better disease control.

— Doxycycline 200 mg/day ± nicotinamide 500–2000 mg/day in divided doses.

— BLISTER trial: doxycycline non-inferior to prednisolone for short-term blister control with significantly fewer serious adverse events at 1 year.

— Ideal for diabetics, osteoporotic patients, and those with high steroid-risk profile.

— Azathioprine 1–3 mg/kg/day — check TPMT activity first; monitor CBC, LFTs every 2 weeks initially.

— Mycophenolate mofetil 1–1.5 g BID — generally better tolerated than azathioprine; monitor CBC, LFTs.

— Methotrexate 10–15 mg/week + folic acid — good option in elderly with mild renal sparing, avoid if CrCl <30, monitor LFTs, CBC.

— Rituximab 1 g IV × 2 doses (2 weeks apart) or 375 mg/m² weekly × 4 — increasing first-line use in severe/refractory BP; screen HBV before infusion.

— Omalizumab (anti-IgE) and dupilumab (anti-IL-4Rα) — promising in case series for IgE-mediated and Th2-skewed BP.

— IVIG 2 g/kg/cycle for refractory cases or when immunosuppression contraindicated.

— Calcium 1200 mg + vitamin D 800 IU daily, bisphosphonate if FRAX elevated, PJP prophylaxis (TMP-SMX) if on prednisone ≥20 mg + second immunosuppressant, PPI if NSAID use or GI risk.

Topical corticosteroids (first-line, all severities when feasible):

Systemic corticosteroids:

Tetracycline-based regimens (mild–moderate, or steroid-sparing):

Steroid-sparing immunosuppressants (add early in moderate-severe):

Refractory disease:

Prophylaxis with systemic steroids ≥20 mg prednisone × ≥4 weeks:

CCS pearl: Always order glucose monitoring, BP checks, and bone-health labs alongside prednisone — Step 3 grades the safety bundle.

Expanded Pharmacology — Steroid-Sparing and Biologic Strategy

— Pre-screen TPMT enzyme activity (or genotype) — homozygous deficient patients risk fatal myelosuppression; intermediate activity → reduce dose by 50%.

— Onset 6–12 weeks; useful long-term steroid-sparer.

— Monitor: CBC + LFTs weekly × 4, then monthly. Watch for pancreatitis, hepatitis, lymphoma risk with long-term use.

— Faster onset than azathioprine (4–8 weeks), better GI tolerance with enteric-coated form.

— Teratogenic — REMS program, two contraceptive methods in reproductive-age women.

— Monitor CBC, LFTs monthly.

— Useful in mild-moderate BP, particularly when MMF/AZA contraindicated.

— Avoid in CrCl <30, significant liver disease, heavy alcohol use.

— Folic acid 1 mg daily (or 5 mg weekly) reduces toxicity.

— Increasingly used earlier in moderate-severe BP, especially when steroids contraindicated.

— Screen HBsAg, anti-HBc, HCV, HIV, TB; vaccinate (inactivated) ≥4 weeks before infusion when possible.

— Risks: infusion reactions, hypogammaglobulinemia with repeat cycles, rare PML, late-onset neutropenia.

— Blocks IL-4Rα → suppresses Th2/eosinophil pathway central to BP pathogenesis.

— Emerging first-line consideration in refractory or steroid-intolerant BP; well tolerated in elderly. Watch for conjunctivitis.

— Stop the offending agent immediately; many cases resolve with withdrawal + topical steroids alone within weeks to months.

— Document allergy/ADR; communicate to PCP and pharmacy.

Why steroid-sparing matters: Prolonged high-dose prednisone in elderly drives mortality through infection, fractures, hyperglycemia, and cardiovascular events — exceeds mortality from BP itself in some cohorts.

Azathioprine:

Mycophenolate mofetil (MMF):

Methotrexate:

Rituximab (anti-CD20):

Dupilumab:

Omalizumab: anti-IgE; useful when total IgE elevated and urticarial component prominent.

IVIG: 2 g/kg over 2–5 days monthly; reserved for refractory/contraindicated immunosuppression. Risks: thrombosis, renal injury, aseptic meningitis, volume overload — caution in CHF.

Drug-induced BP specifics:

Board pearl: In a diabetic on sitagliptin who develops BP, switching to an SGLT2 inhibitor or insulin plus topical clobetasol may eliminate need for systemic immunosuppression entirely — a frequently tested management vignette.

Special Populations — Elderly and Renal/Hepatic Impairment

— Hyperglycemia, osteoporotic fractures, delirium, infection, hypertension, cataracts, sarcopenia, skin fragility, mood changes.

— Prednisone ≤0.5 mg/kg/day is preferred ceiling; >0.75 mg/kg/day increases 1-year mortality without efficacy gain.

— Strongly favor whole-body topical clobetasol when feasible — equal efficacy, lower mortality.

— Steroids worsen control; pre-emptively up-titrate insulin or add basal coverage; monitor fingersticks QID during taper.

— Avoid gliptins (causal in BP) — use SGLT2 inhibitor, GLP-1 agonist, metformin, or insulin instead.

— Methotrexate contraindicated if CrCl <30; dose-reduce 30–50 if 30–50.

— Mycophenolate: no dose adjustment for renal disease but watch GI tolerance; check trough if available in refractory cases.

— Azathioprine: reduce dose if CrCl <30; monitor closely.

— Doxycycline: safe in renal impairment (hepatic clearance) — useful steroid-sparer in dialysis patients.

— Avoid NSAIDs for pruritus-related discomfort.

— Avoid or reduce azathioprine and methotrexate.

— MMF generally safe; doxycycline acceptable with monitoring.

— Prednisone: caution in cirrhosis (fluid retention, encephalopathy risk).

— Simplify regimen; once-daily dosing preferred.

— Topical regimens require caregiver education and physical capacity — assess before prescribing whole-body clobetasol.

— Monitor for steroid-induced delirium and falls; reconcile psychotropics.

— Calcium 1200 mg + vitamin D 800–1000 IU daily.

— Oral bisphosphonate (alendronate, risedronate) unless contraindicated; consider denosumab if eGFR <35 or pill burden concerns.

— Baseline DEXA; repeat at 1–2 years.

The default BP patient is elderly — make geriatric-aware choices the rule, not the exception.

Steroid risk in elderly:

Diabetes coexistence:

Renal impairment:

Hepatic impairment:

Polypharmacy and dementia:

Bone protection (mandatory if prednisone ≥7.5 mg/day for ≥3 months):

Step 3 management: In a 78-year-old with dementia, DM2 on sitagliptin, and CKD stage 3 developing BP, the optimal regimen is stop sitagliptin → start SGLT2i + whole-body topical clobetasol + doxycycline/nicotinamide + calcium/vitamin D/bisphosphonate, avoiding systemic steroids and methotrexate. This is a high-yield Step 3 vignette.

Special Populations — Pregnancy, Pediatrics, and Pemphigoid Variants

— Pregnancy-specific autoimmune subepidermal blistering disease, same target (BP180 NC16A) as BP.

— Onset 2nd/3rd trimester or immediate postpartum; periumbilical urticarial plaques evolving into tense bullae spreading peripherally.

— Mild risk of prematurity and small-for-gestational-age infants; ~10% of newborns have transient skin lesions from passive antibody transfer.

— Recurs in subsequent pregnancies, often earlier and more severe; may flare with menses or OCPs.

— Treatment: topical clobetasol first; prednisone 0.5 mg/kg/day for moderate-severe (safest systemic in pregnancy — minimal placental transfer due to placental 11-β-HSD2).

— Avoid in pregnancy: methotrexate (teratogen, abortifacient), mycophenolate (REMS, teratogen), tetracyclines after 15 weeks (tooth/bone).

— Safe-ish: prednisone, azathioprine (Category D but used in IBD/transplant pregnancies when needed), IVIG.

— Two peaks: <1 year (acral and facial bullae prominent, often genital/perineal) and childhood (more BP-like distribution).

— Excellent response to topical clobetasol ± short course of oral steroids; rarely needs immunosuppressants.

— Often post-vaccination triggered; usually self-limited within 1 year.

— Predominant mucosal involvement (oral, ocular, nasopharyngeal, genital, esophageal) with scarring.

— Ocular involvement → symblepharon, entropion, blindness — urgent ophthalmology referral.

— Anti-laminin-332 subtype: screen for malignancy (solid tumors).

— Treatment more aggressive: dapsone, cyclophosphamide, rituximab.

— "String of pearls" annular vesicles; drug-induced (especially vancomycin) — discontinue trigger.

— DIF: linear IgA at BMZ (vs. IgG/C3 in BP).

Pemphigoid gestationis (PG, formerly herpes gestationis):

Pediatric/infantile BP (very rare):

Mucous membrane pemphigoid (cicatricial pemphigoid) — key distinction:

Brunsting-Perry pemphigoid: localized cicatricial variant on scalp/head/neck.

Anti-p200 pemphigoid: mimics BP clinically but younger patients, often psoriasis-associated, antibodies to laminin γ1.

Linear IgA bullous dermatosis:

Board pearl: Periumbilical bullae in a pregnant woman = pemphigoid gestationis; vancomycin + new annular vesicles = linear IgA disease. Both are commonly confused with BP on exams.

Complications and Adverse Outcomes

— Secondary bacterial infection of eroded skin: Staphylococcus aureus (including MRSA), Streptococcus pyogenes — leading to cellulitis, bacteremia, sepsis. Most common cause of BP-related death.

— Fluid, electrolyte, and protein loss through denuded skin in extensive disease — similar physiology to burn patient; hypoalbuminemia, hypothermia, dehydration.

— Post-inflammatory hyperpigmentation; milia and scarring uncommon unless deep erosion or infection.

— Pruritus-related sleep disruption, depression, reduced quality of life — especially in elderly.

— Functional decline, deconditioning, pressure injuries from bedbound state.

— Systemic steroid toxicity: hyperglycemia/new-onset DM, osteoporotic fractures (vertebral, hip), avascular necrosis, hypertension, fluid retention/CHF exacerbation, cataracts, glaucoma, peptic ulcer, infection (bacterial, fungal, PJP, reactivation TB/HBV), mood disturbance, delirium, myopathy, skin fragility.

— Immunosuppressant toxicities:

— Azathioprine: myelosuppression, hepatitis, pancreatitis, lymphoma risk.

— MMF: GI intolerance, leukopenia, teratogenicity.

— Methotrexate: hepatotoxicity, pneumonitis, cytopenias, mucositis.

— Rituximab: infusion reactions, hypogammaglobulinemia, HBV reactivation, rare PML.

— Doxycycline: photosensitivity, esophagitis (take upright with water), C. difficile.

— 1-year mortality 10–40% in elderly BP — among the highest of dermatologic diseases.

— Predictors: age >80, low albumin, extensive BSA, dementia, bedbound status, high-dose steroid exposure.

— Pressure injuries, DVT (immobility + inflammation), hospital-acquired pneumonia, delirium.

— VTE prophylaxis in any hospitalized BP patient unless contraindicated.

— 30–50% relapse during taper or within first year off therapy; rising anti-BP180 titer often heralds it.

— Triggers: infection, surgery, drug rechallenge.

Disease-related complications:

Treatment-related complications (often outweigh disease in elderly):

Mortality:

Hospital-related risks:

Relapse:

Step 3 management: Any hospitalized BP patient with fever, increasing erythema, or purulent crusting needs blood cultures, wound cultures, empiric anti-staphylococcal coverage (vancomycin if MRSA risk), and reassessment of immunosuppression dose. Sepsis is the leading cause of death — treat aggressively.

When to Escalate Care — Hospital, Consult, and Multidisciplinary Triage

— Extensive disease (>30% BSA or >10–20 new blisters/day) with fluid/electrolyte derangement.

— Suspected secondary infection with systemic signs (fever, leukocytosis, hemodynamic instability).

— Inability to maintain oral intake (mucosal involvement, frailty).

— Failure of outpatient therapy or rapid progression despite topical clobetasol.

— Severe comorbidity flare (decompensated CHF, uncontrolled diabetes from steroids, GI bleed).

— Social: inadequate caregiver support to apply whole-body topical therapy or monitor systemic immunosuppression.

— Sepsis with hemodynamic compromise; high-output skin failure with severe hypoalbuminemia, hypothermia, electrolyte instability.

— Manage analogously to burn-like care: warm environment, careful fluid balance, nutritional support (high-protein, high-calorie), pressure-injury prevention.

— Dermatology — confirm diagnosis (biopsy + DIF), guide systemic therapy and tapering.

— Wound care/nursing — non-adherent dressings (petrolatum gauze, silicone), gentle bathing, no aggressive debridement of intact bullae roof (acts as biologic dressing).

— Endocrinology for steroid-induced hyperglycemia in brittle diabetics.

— Ophthalmology if any ocular symptoms (rules out mucous membrane pemphigoid).

— Geriatrics/palliative care for goals-of-care conversations in frail patients; BP can be a "marker of frailty" and disease trajectory.

— ID for refractory infection or pre-rituximab screening counseling.

— Aspirate large tense bullae with sterile needle but leave roof intact — reduces pain and discomfort while preserving epidermal barrier.

— Apply petrolatum or non-adherent dressing; avoid adhesive tapes directly on skin.

— Daily gentle cleansing with dilute chlorhexidine or saline; monitor for infection signs.

— Confirm caregiver can apply topical clobetasol BID; arrange home health if needed.

— Pre-fill prescriptions, set 1-week dermatology follow-up post-discharge.

— Document tapering schedule clearly in discharge summary.

Indications for hospitalization:

ICU/step-down criteria:

Consultations:

Care of bullae (nursing orders for CCS):

Transition planning:

CCS pearl: Admit a febrile BP patient with extensive erosions and order: IV fluids, blood + wound cultures, empiric vancomycin + cefepime (or per local antibiogram), dermatology consult, non-adherent dressings, VTE prophylaxis, fingerstick glucose Q6h, daily CBC/BMP/albumin, ophthalmology if ocular symptoms. Then continue or initiate clobetasol and reassess systemic immunosuppression.

Key Differentials — Other Autoimmune Bullous Diseases

— Flaccid bullae, painful oral erosions (often the presenting feature), middle-aged adults.

— Nikolsky sign positive; intraepidermal split, suprabasal acantholysis on H&E.

— DIF: intercellular "fishnet" IgG and C3 in epidermis; antibodies to desmoglein 3 (mucosa) and desmoglein 1 (skin).

— Treatment: high-dose steroids + rituximab (first-line) per current AAD guidelines.

— Subepidermal blistering with trauma-induced bullae on extensor surfaces and acral sites; heals with scarring and milia.

— Salt-split IIF: dermal (floor) binding (vs. epidermal in BP).

— Antibodies to type VII collagen; associated with IBD.

— Intensely pruritic grouped vesicles on extensor surfaces (elbows, knees, buttocks, scalp); rarely intact vesicles due to scratching.

— DIF: granular IgA in dermal papillae; associated with celiac disease and HLA-DQ2/DQ8.

— Treatment: gluten-free diet + dapsone (check G6PD first).

— "Crown of jewels" annular vesicles; often drug-induced (vancomycin).

— DIF: linear IgA at BMZ.

Pemphigus vulgaris (PV):

Pemphigus foliaceus: superficial flaccid blisters/crusts on scalp, face, chest; no mucosal involvement; anti-desmoglein 1.

Paraneoplastic pemphigus: severe painful stomatitis, polymorphic skin lesions, association with lymphoproliferative malignancies (CLL, NHL, Castleman); high mortality from bronchiolitis obliterans.

Mucous membrane (cicatricial) pemphigoid: predominant mucosal disease with scarring (ocular, oral, esophageal); urgent ophthalmology.

Epidermolysis bullosa acquisita (EBA):

Bullous SLE: subepidermal bullae on sun-exposed skin in SLE patients; dermal-side antibodies to type VII collagen; responds dramatically to dapsone.

Dermatitis herpetiformis (DH):

Linear IgA bullous dermatosis:

Anti-p200 pemphigoid: BP-like clinically, younger patients, psoriasis association; antibodies to laminin γ1.

Key distinction: All these are distinguished primarily by DIF pattern + target antigen, not clinical appearance alone. The Step 3 algorithm: clinical suspicion → biopsy with DIF → ELISA/IIF (salt-split) for confirmation and subtype.

Key Differentials — Non-Autoimmune Mimics

— Children most commonly; Staphylococcus aureus exfoliative toxin cleaves desmoglein 1.

— Flaccid bullae with honey-colored crusts on face, trunk, extremities.

— Treatment: topical mupirocin or oral cephalexin/dicloxacillin.

— Drug reaction (sulfa, anticonvulsants, allopurinol, NSAIDs) 1–3 weeks after exposure.

— Prodromal fever, mucositis (oral, ocular, genital) — prominent — followed by dusky macules → flaccid bullae and sheet-like sloughing; Nikolsky positive.

— Histology: full-thickness epidermal necrosis with minimal inflammation — distinct from BP.

— Manage in burn/ICU setting; stop offending drug, supportive care.

— Linear or grouped lesions, exposure history, distribution on exposed skin or in burrow areas (web spaces, genitals).

— Scabies in elderly nursing-home residents can mimic BP non-bullous phase — always do scabies prep before committing to BP diagnosis.

— Tense bullae and erosions on sun-exposed dorsa of hands, hypertrichosis, skin fragility.

— Associated with HCV, alcohol, hemochromatosis, estrogen; elevated urinary porphyrins.

— Treatment: phlebotomy, low-dose hydroxychloroquine, sun protection, treat HCV.

Bullous impetigo:

Stevens-Johnson syndrome / Toxic epidermal necrolysis (SJS/TEN):

Bullous drug eruptions (non-SJS): fixed drug eruption (single recurring site, often genital, after NSAIDs/sulfa), bullous erythema multiforme (post-HSV).

Bullous arthropod bites/scabies:

Bullous contact dermatitis: geometric/linear pattern, history of exposure (poison ivy, nickel, topical agents); patch testing diagnostic.

Friction blisters, burns, frostbite: mechanical/thermal history obvious; localized.

Porphyria cutanea tarda (PCT):

Pseudoporphyria: similar appearance, often induced by NSAIDs (naproxen), furosemide, voriconazole — overlapping drug list with BP triggers, but porphyrins normal.

Edema blisters: in patients with severe lower-extremity edema (CHF, nephrotic, cirrhosis); clear bullae on legs, resolve with diuresis.

Diabetic bullae (bullosis diabeticorum): spontaneous tense bullae on acral skin in long-standing diabetes; self-resolving.

Board pearl: Tense bullae + sun-exposed dorsa of hands + alcohol/HCV → think PCT, not BP. Order urine porphyrins and HCV serology before committing to immunosuppression.

Long-Term Plan, Maintenance, and Secondary Prevention

— Induction (control phase): until no new blisters × 2 weeks — typically 1–4 weeks on systemic steroids or 2–4 weeks on potent topical.

— Consolidation: maintain current dose for 2 weeks after control.

— Maintenance/taper: gradual reduction over 6–12 months; relapse risk highest during this phase.

— Reduce prednisone by ~25% every 2–4 weeks; slow to 5–10 mg decrements once <20 mg/day; 5–10 mg/day is often a maintenance "floor."

— Slow topical clobetasol from BID daily → BID 3×/week → BID 2×/week → off over 4 months.

— Continue steroid-sparing agent for 12–18 months of disease quiescence before attempting withdrawal.

— Track anti-BP180 NC16A ELISA every 3 months during taper; rising titer predicts relapse weeks ahead.

— Patient self-monitoring: new pruritus, urticarial patches, or single new blister warrants prompt re-evaluation.

— Document drug allergy/ADR prominently for offending agent (gliptin, furosemide, etc.); flag in EHR.

— Counsel patient and family — show medication list at every visit.

— Sun protection (some immunosuppressants increase skin cancer risk).

— Before/during immunosuppression: inactivated influenza annually, pneumococcal (PCV20 or PCV15+PPSV23), shingles (recombinant Shingrix), COVID-19, RSV per age and risk.

— Avoid live vaccines (MMR, varicella, live zoster, yellow fever) while on significant immunosuppression — give ≥4 weeks before starting or ≥3 months after stopping when possible.

— Continue calcium/vitamin D, bisphosphonate; DEXA every 1–2 years.

Therapeutic phases:

Tapering principles:

Relapse monitoring:

Trigger avoidance and secondary prevention:

Vaccinations:

Bone health on chronic steroids:

Cancer screening: age-appropriate per USPSTF; no routine paraneoplastic workup unless atypical features.

General prevention: skin emollients daily, gentle cleansers, avoid hot water and trauma, prevent xerosis-related itch that can simulate relapse.

Step 3 management: At every visit during taper, document: current blister count, BPDAI or BSA, anti-BP180 titer, weight, BP, glucose, CBC/CMP, taper plan with specific dates, vaccination status, bone-protection status, and a relapse action plan for the patient.

Follow-Up, Monitoring Parameters, and Counseling

— Week 1–2 after diagnosis: assess response, side effects, adherence; phone or visit.

— Monthly during active treatment and taper for first 6 months.

— Every 3 months in maintenance/stable disease.

— Annually after sustained remission off therapy.

— CBC, CMP (glucose, K, Cr, LFTs) every 2 weeks × 1 month, then monthly.

— HbA1c every 3 months if on prednisone or diabetic.

— Lipid panel annually.

— Anti-BP180 NC16A every 3 months during taper.

— TB screening annually on chronic immunosuppression.

— Skin cancer screen annually (chronic immunosuppression risk).

— Azathioprine/MMF: CBC, LFTs monthly.

— Methotrexate: CBC, LFTs, Cr every 4–8 weeks; annual chest imaging if symptoms.

— Rituximab: CBC, IgG levels at 6 months; hepatitis surveillance.

— Doxycycline: screen for photosensitivity, GI symptoms.

— How to apply topical clobetasol — sparing face, washing hands after, watching for atrophy.

— How to care for bullae — do not aggressively unroof; clean gently, cover with non-adherent dressing.

— Warning signs requiring urgent contact: spreading redness, fever, purulent discharge, new mucosal lesions, eye pain or vision change, rapid increase in blister count.

— Steroid sick-day rules if on ≥5 mg prednisone >3 weeks: stress-dose for major illness/surgery; medical alert bracelet.

— Bone health, fall prevention, weight monitoring for steroid users.

— Screen for depression (PHQ-9), sleep disruption from pruritus, caregiver burden.

— Support groups (IPPF — International Pemphigus and Pemphigoid Foundation).

— Physical therapy for deconditioning in extensive disease.

— Occupational therapy for ADLs in elderly.

Follow-up cadence:

Monitoring labs (while on systemic therapy):

Drug-specific monitoring:

Patient/caregiver counseling:

Quality-of-life and psychosocial:

Rehabilitation:

Board pearl: Anti-BP180 NC16A ELISA every 3 months during taper is the most testable laboratory monitoring tool — rising titer signals impending relapse and warrants slower taper or dose increase before clinical flare.

Ethical, Legal, and Patient Safety Considerations

— Elderly patients (often with mild cognitive impairment) require careful capacity assessment for consent to long-term steroids, MMF, or rituximab.

— Document risk-benefit discussion: infection, fractures, malignancy risk, diabetes, mortality; identify health care proxy and surrogate decision-makers early.

— In dementia, involve POA and align therapy with goals of care — sometimes topical-only management is the ethical choice over aggressive immunosuppression.

— BP can be a marker of advanced frailty; 1-year mortality 10–40%.

— Initiate palliative care conversations when disease and comorbidities limit prognosis; comfort-focused topical therapy is appropriate in end-of-life care.

— At hospital discharge, clearly communicate the prednisone taper schedule, follow-up dates, and lab schedule to PCP and patient; abrupt steroid discontinuation can cause adrenal crisis in patients on ≥5 mg × ≥3 weeks.

— Reconcile medications — ensure offending drug (gliptin, furosemide) is removed from active list and flagged as ADR/allergy.

— Send dermatology and PCP a written plan with specific milestones.

— Elder abuse/neglect screening: unexplained bruising, poor hygiene, weight loss, or pressure injuries in nursing-home BP patients trigger Adult Protective Services reporting in most US states.

— Fall risk assessment in elderly on steroids; review home environment.

— Avoid co-prescribing NSAIDs (GI bleed with steroids), live vaccines (during immunosuppression), and rifampin (drug interactions with prednisone).

— TB and HBV screening before immunosuppression — failure is a sentinel safety event.

— Pregnancy testing and contraception counseling for any reproductive-age patient on MMF (REMS) or MTX.

— Rituximab and biologics carry significant cost; verify prior authorization and patient out-of-pocket; use manufacturer assistance programs.

— Caregiver support is essential — assess and arrange home health, especially when topical regimens require whole-body application.

Informed consent for systemic immunosuppression:

Goals-of-care and palliative considerations:

Transition-of-care risks (high-yield Step 3):

Mandatory and protective reporting:

Patient safety practices:

Health-system context:

Board pearl: A common Step 3 vignette: an 80-year-old discharged on prednisone 40 mg with a 6-month taper develops fever and hypotension 5 days after abruptly stopping prednisone at home due to confusion about the schedule. Diagnosis: adrenal crisis. Prevention: explicit written taper, teach-back at discharge, and PCP follow-up within 1 week.

High-Yield Associations and Rapid-Fire Clinical Facts

Antigens: BP180 (collagen XVII, NC16A domain) and BP230 — hemidesmosomal proteins.

Histology: subepidermal blister with eosinophil-rich infiltrate; non-bullous phase shows eosinophilic spongiosis.

DIF: linear IgG and C3 along basement membrane zone (C3 most sensitive ~90%).

Salt-split skin IIF: antibodies bind epidermal (roof) side = BP; dermal (floor) = EBA, bullous SLE, anti-p200.

ELISA: anti-BP180 NC16A correlates with disease activity and predicts relapse.

Peripheral eosinophilia in ~50% of patients.

Classic patient: 70+ year-old with tense bullae in flexures, negative Nikolsky, severe pruritus, minimal mucosal disease.

Drug triggers (memorize): DPP-4 inhibitors (gliptins), immune checkpoint inhibitors (nivolumab, pembrolizumab), furosemide, spironolactone, penicillamine, sulfasalazine, NSAIDs.

Disease associations: Parkinson, dementia, stroke, multiple sclerosis (strong neurologic link); psoriasis; rarely paraneoplastic.

Mortality: 1-year 10–40% in elderly — among highest in dermatology; infection is leading cause.

First-line for mild-moderate: whole-body clobetasol 0.05% ointment — equal efficacy to oral prednisone with lower mortality (Joly trial).

First-line for moderate-severe: prednisone 0.5 mg/kg/day (avoid >0.75 mg/kg/day in elderly).

Steroid-sparing options: doxycycline + nicotinamide (BLISTER trial: non-inferior short-term), azathioprine (check TPMT), MMF, methotrexate.

Refractory: rituximab, dupilumab, omalizumab, IVIG.

Vs. pemphigus vulgaris: PV has flaccid bullae, painful oral erosions, positive Nikolsky, intraepidermal split, anti-desmoglein 3/1.

Vs. dermatitis herpetiformis: DH has grouped vesicles on extensors, granular IgA in dermal papillae, celiac association, treat with gluten-free + dapsone.

Vs. linear IgA: drug-induced (vancomycin), "string of pearls," linear IgA on DIF.

Pemphigoid gestationis: periumbilical bullae in 2nd/3rd trimester pregnancy, same BP180 NC16A target.

Cicatricial (mucous membrane) pemphigoid: scarring, ocular involvement — anti-laminin-332 subtype linked to malignancy.

Board pearl: If the stem says "elderly + DPP-4 inhibitor + tense bullae + linear C3 at BMZ," the answer is bullous pemphigoid — stop the gliptin and start topical clobetasol.

Board Question Stem Patterns

— 78-year-old with months of pruritus → tense bullae in axillae and groin → Nikolsky negative.

— Best next step: punch biopsy of lesional skin (H&E) plus perilesional skin in Michel's medium (DIF).

— Diagnosis: bullous pemphigoid (linear IgG/C3 at BMZ).

— Diabetic on sitagliptin for 4 months develops pruritic bullae.

— Best initial step: discontinue sitagliptin, switch to SGLT2 inhibitor or insulin; biopsy + DIF; initiate topical clobetasol.

— Painful oral erosions + flaccid skin bullae + positive Nikolsky in 50-year-old.

— Answer: pemphigus vulgaris (anti-desmoglein 3); not BP.

— Subepidermal bullae, DIF linear IgG, salt-split IIF binds dermal (floor) side.

— Answer: epidermolysis bullosa acquisita (anti-type VII collagen), not BP.

— 28-year-old, 32 weeks pregnant, urticarial periumbilical plaques evolving to bullae.

— Answer: PG; treat with topical clobetasol, escalate to prednisone if needed; counsel on recurrence in future pregnancies.

— 85-year-old with diabetes, osteoporosis, moderate BP.

— Answer: whole-body topical clobetasol 0.05% ± doxycycline/nicotinamide; avoid high-dose oral prednisone.

— BP patient 9 months into prednisone taper, asymptomatic. Best lab to predict relapse?

— Answer: anti-BP180 NC16A ELISA.

— Patient on vancomycin develops annular vesicles ("string of pearls"); DIF shows linear IgA.

— Answer: linear IgA bullous dermatosis; stop vancomycin.

— BP patient, 80 years, on prednisone 40 mg, presents with fever and hypotension.

— Answer: sepsis from skin infection — most common cause of mortality in BP.

— Before starting azathioprine, what to check? TPMT activity (and HBV, HCV, HIV, TB).

Stem 1 — Classic presentation:

Stem 2 — Drug-induced BP:

Stem 3 — Distinguishing from pemphigus vulgaris:

Stem 4 — Salt-split skin:

Stem 5 — Pemphigoid gestationis:

Stem 6 — Best initial therapy in frail elderly:

Stem 7 — Monitoring for relapse:

Stem 8 — Linear IgA vs. BP:

Stem 9 — Most common cause of death:

Stem 10 — Pre-immunosuppression workup:

Board pearl: Recognize the 2-biopsy rule (H&E from lesion + DIF from perilesion) and the salt-split direction (roof vs. floor) — these two concepts dominate BP questions.

One-Line Recap

Bullous pemphigoid is an IgG-mediated subepidermal blistering disease of the elderly targeting BP180/BP230 at the dermal-epidermal junction — diagnosed by lesional H&E plus perilesional DIF (linear IgG/C3 at the BMZ) and managed with high-potency topical clobetasol as first line, with systemic prednisone, doxycycline/nicotinamide, or steroid-sparing agents reserved for moderate-severe or refractory disease, always after stopping any offending drug (especially DPP-4 inhibitors).

Diagnosis: Tense bullae + negative Nikolsky in an elderly patient → biopsy edge of bulla for H&E + perilesional skin in Michel's medium for DIF (linear IgG/C3 at BMZ); confirm with anti-BP180 NC16A ELISA and salt-split IIF (epidermal/roof binding).

First-line therapy: Whole-body clobetasol 0.05% ointment for mild-moderate disease (equal efficacy, lower mortality than oral steroids in elderly per Joly trial); prednisone 0.5 mg/kg/day for severe disease with early steroid-sparing agent (azathioprine, MMF, MTX) or doxycycline + nicotinamide (BLISTER trial: non-inferior short-term).

Always: stop offending drugs (gliptins, checkpoint inhibitors, furosemide), screen HBV/HCV/HIV/TB before immunosuppression, add calcium/vitamin D + bisphosphonate for chronic steroids, monitor anti-BP180 titer every 3 months during taper, and prevent the leading killer — skin infection/sepsis.

Step 3 management: Frame BP as a geriatric, multi-system, longitudinal problem: coordinate dermatology + PCP + caregivers, document a clear taper schedule, prevent adrenal crisis with explicit teach-back at discharge, flag the offending drug as ADR in the EHR, and align therapy intensity with goals of care in frail patients.